ADCT-901 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objectives of this study are to identify the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced solid tumors (like cholangiocarcinoma, ovarian, prostate cancer, renal cell carcinoma, and TNBC) that are measurable and have not responded to or can't tolerate current treatments. Participants should not have active severe diarrhea or eye diseases, recent serious infections requiring IV treatment, symptomatic brain metastases or leptomeningeal disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of ADCT-901 as monotherapy until disease progression, adverse event, or other discontinuation criteria
Dose Expansion
Participants receive ADCT-901 monotherapy at the dose identified as the RP2D/MTD in Part 1 until disease progression, adverse event, or other discontinuation criteria
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ADCT-901
Find a Clinic Near You
Who Is Running the Clinical Trial?
ADC Therapeutics S.A.
Lead Sponsor